Biphasic glomerular hypertrophy in rats administered puromycin aminonucleoside

Area of Science:

• Nephrology
• Pathology
• Renal Physiology

Background:

• Glomerular hypertrophy is increasingly recognized as a critical factor in focal and segmental glomerulosclerosis (FSGS) development.
• The puromycin aminonucleoside (PAN) rat model has been a standard for FSGS research, though its role in glomerular hypertrophy was previously unclear.

Purpose of the Study:

• To investigate the presence of glomerular hypertrophy in the PAN rat model of FSGS.
• To determine the contribution of glomerular capillary growth to hypertrophy in this model.

Main Methods:

• Female Sprague-Dawley rats were administered PAN or saline subcutaneously over 10 weeks.
• Tissue analysis at 7 and 13 weeks utilized unbiased stereological methods to assess glomerular parameters.
• Statistical analysis included two-way ANOVA to evaluate the effects of PAN and time.

Main Results:

• PAN-treated rats exhibited significant glomerular tuft and renal corpuscle volume increases (48% at 7 weeks, 63% at 13 weeks).
• FSGS was minimal at 13 weeks, indicating hypertrophy precedes significant sclerosis.
• PAN significantly affected capillary length, surface area, and diameter, suggesting capillary remodeling.

Conclusions:

• The PAN model demonstrates a biphasic pattern of glomerular hypertrophy.
• Early hypertrophy (to 7 weeks) is driven by increased capillary length.
• Later enlargement (7-13 weeks) involves increased capillary diameter and/or mesangial matrix expansion.